Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
RANK/TNFRSF11A Antibody (64C1385.1) - BSA Free, Novus Biologicals™

Mouse Monoclonal Antibody has been used in 2 publications
Supplier: Novus Biologicals NBP224702SS
Description
RANK/TNFRSF11A Monoclonal specifically detects RANK/TNFRSF11A in Human, Mouse samples. It is validated for Western Blot, Flow Cytometry, Immunohistochemistry, Immunoprecipitation, Immunohistochemistry-Paraffin, CyTOF-ready, Dual RNAscope ISH-IHC.Specifications
RANK/TNFRSF11A | |
Monoclonal | |
1.0 mg/mL | |
Western Blot 1-2 μg/mL, Flow Cytometry 5 μg/10^6 cells, Immunohistochemistry, Immunoprecipitation 1-2 μg/mL, Immunohistochemistry-Paraffin 5 μg/mL, CyTOF-ready, Dual RNAscope ISH-IHC | |
CD265, CD265 antigen, FEO, loss of heterozygosity, 18, chromosomal region 1, ODFROSTS, OFE, OPTB7, Osteoclast differentiation factor receptor, PDB2, RANKLOH18CR1, Receptor activator of NF-KB, receptor activator of nuclear factor-kappa B, TRANCER, tumor necrosis factor receptor superfamily member 11A, tumor necrosis factor receptor superfamily, member 11a, activator of NFKB, tumor necrosis factor receptor superfamily, member 11a, NFKB activator | |
Mouse | |
Protein G purified | |
RUO | |
Primary | |
This antibody is reactive to Human and Mouse. | |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. | |
IgG1 λ |
Western Blot, Flow Cytometry, Immunohistochemistry, Immunoprecipitation, Immunohistochemistry (Paraffin), CyTOF | |
64C1385.1 | |
Unconjugated | |
Q9Y6Q6 | |
TNFRSF11A | |
A recombinant protein containing the extracellular domain (amino acids 33-208) of human RANK was used as immunogen. | |
0.025 mg | |
Cell Cycle and Replication | |
8792 | |
Human, Mouse | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction